{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:04:08Z","timestamp":1780455848030,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","diabet-metabolism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.diabet.2016.05.006","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T06:19:42Z","timestamp":1465712382000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics"],"prefix":"10.1016","volume":"42","author":[{"given":"A.J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2016.05.006_bib0325","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2016.05.006_bib0330","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2016.05.006_bib0335","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.diabet.2016.05.006_bib0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2016.02.134","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","volume":"212","author":"Ghosh","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0345","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2016.05.006_bib0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.diabet.2014.03.004","article-title":"Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0355","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0360","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0365","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabet.2015.12.005","article-title":"Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","article-title":"The EMPA-REG study: what has it told us? A diabetologist's perspective","volume":"30","author":"DeFronzo","year":"2016","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.diabet.2016.05.006_bib0375","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2016.05.006_bib0380","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jash.2016.01.009","article-title":"Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis","volume":"10","author":"Kimura","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabet.2016.05.006_bib0385","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2016.05.006_bib0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG \u2013\u00a0the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.diabet.2016.05.006_bib0395","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2016.05.006_bib0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/2230-8210.176361","article-title":"Empagliflozin: not just a glorified diuretic","volume":"20","author":"John","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0405","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14656566.2014.879118","article-title":"Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2016.05.006_bib0410","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14656566.2014.879117","article-title":"Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2016.05.006_bib0415","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","article-title":"Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?","volume":"33","author":"Imprialos","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2016.05.006_bib0420","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabet.2016.05.006_bib0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0430","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diabet.2016.05.006_bib0440","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2016.05.006_bib0445","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obesity Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0450","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obesity Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0455","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2016.05.006_bib0460","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0465","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","article-title":"Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure","volume":"201","author":"Takeuchi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0475","first-page":"1","article-title":"Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials","author":"Johnsson","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabet.2016.05.006_bib0480","article-title":"No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM)","volume":"24","author":"Toto","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0485","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14656566.2016.1109629","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials","volume":"17","author":"Parveen","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2016.05.006_bib0490","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.diabet.2016.05.006_bib0495","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.2337\/dc11-s246","article-title":"Diuretic treatment of hypertension","volume":"34","author":"Grossman","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2016.05.006_bib0500","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ajh\/hpv134","article-title":"Impact of antihypertensive agents on central systolic blood pressure and augmentation index: a meta-analysis","volume":"29","author":"McGaughey","year":"2016","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.diabet.2016.05.006_bib0505","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jch.12622","article-title":"Comparison of the effect of thiazide diuretics and other antihypertensive drugs on central blood pressure: cross-sectional analysis among nondiabetic patients","volume":"17","author":"Moura","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl. 2","key":"10.1016\/j.diabet.2016.05.006_bib0510","first-page":"B65","article-title":"Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis","volume":"23","author":"Lievre","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2016.05.006_bib0515","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.1996.03540230036032","article-title":"Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension","volume":"276","author":"Curb","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2016.05.006_bib0520","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0525","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabet.2016.05.006_bib0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0535","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","article-title":"Thiazide and loop diuretics","volume":"13","author":"Sica","year":"2011","journal-title":"J Clin Hypertens. (Greenwich)"},{"key":"10.1016\/j.diabet.2016.05.006_bib0540","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2016.05.006_bib0545","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2016.05.006_bib0550","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2016.05.006_bib0555","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jchf.2015.06.014","article-title":"Prognostic value of estimated plasma volume in heart failure","volume":"3","author":"Duarte","year":"2015","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.diabet.2016.05.006_bib0560","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2016.05.006_bib0565","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/1440-1681.12156","article-title":"Mineralocorticoid receptor and cardiac arrhythmia","volume":"40","author":"Gravez","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0570","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabet.2016.05.006_bib0575","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12872-016-0198-2","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.diabet.2016.05.006_bib0580","first-page":"121","article-title":"The effect of diuretics on red blood cell microrheological parameters in female hypertensive patients","volume":"33","author":"Muravyov","year":"2005","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.diabet.2016.05.006_bib0585","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.ijcard.2013.07.241","article-title":"Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry","volume":"168","author":"Oh","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0590","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.amjmed.2014.06.009","article-title":"Hemoconcentration-guided diuresis in heart failure","volume":"127","author":"Vaduganathan","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2016.05.006_bib0595","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","article-title":"Metabolic complications associated with use of diuretics","volume":"31","author":"Palmer","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0600","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"Zhao","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2016.05.006_bib0605","first-page":"A265","article-title":"Empagliflozin has no discernible effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight","volume":"63","author":"Jordan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2016.05.006_bib0610","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-006-0359-4","article-title":"Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes","volume":"49","author":"Tarnow","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2016.05.006_bib0615","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0620","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2016.05.006_bib0625","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6 Suppl. 1","key":"10.1016\/j.diabet.2016.05.006_bib0630","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1262-3636(14)72692-8","article-title":"SGLT-2 inhibition in patients with kidney disease","volume":"40","author":"Gilbert","year":"2014","journal-title":"Diabetes Metab"},{"issue":"6 Suppl. 1","key":"10.1016\/j.diabet.2016.05.006_bib0635","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1262-3636(14)72691-6","article-title":"Beyond glycosuria: exploring the intrarenal effects of SGLT(-)(2) inhibition in diabetes","volume":"40","author":"Thomas","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2016.05.006_bib0640","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2014.12.018","article-title":"Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study","volume":"37","author":"Heise","year":"2015","journal-title":"Clin Ther"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363616304098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363616304098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:27:36Z","timestamp":1536636456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363616304098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1262363616304098"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2016.05.006","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2016.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}